Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein.

Overexpression of bcl-2 delays the onset of apoptosis in lymphohematopoietic cells. We measured levels of bcl-2 protein in normal and leukemic human B-cell progenitors with a specific monoclonal antibody and flow cytometry. Normal immature B cells had low levels of bcl-2 protein; the intensity of fluorescence, expressed as molecules of soluble fluorochrome per cell, within CD10+ cells was 3,460 +/- 1,050 (mean +/- SD; 5 samples). In 16 cases of B-lineage acute lymphoblastic leukemia (ALL), cells had levels of bcl-2 that were strikingly higher than those of their normal counterparts (33,560 +/- 14,570; P < .001 by t-test analysis). We next investigated whether the intensity of bcl-2 expression correlated with the resistance of immature B cells to in vitro culture. In 12 cases of B-lineage ALL, the cells recovered after 7 days of culture on allogeneic bone marrow stromal layers were 69% to 178% (median, 95.5%) of those originally seeded. Prolonged survival of leukemic cells in vitro was observed even in the absence of stromal layers in 6 of these 12 cases; the intensity of bcl-2 protein expression in these cases was 45,000 +/- 13,270, compared with 21,500 +/- 7,260 in the 6 cases in which greater than 99.5% of cells rapidly died by apoptosis under the same culture conditions (P = .003). Five immature B-cell lines, continuously growing in the absence of stroma, had the highest bcl-2 expression (79,400 +/- 20,330). By contrast, most normal CD19+, sIg-immature B cells died despite the presence of bone marrow stromal layers; 9.7% to 28.2% were recovered after 7 days of culture in three experiments. We conclude that abnormal bcl-2 gene expression influences the survival ability of B-cell progenitors. This may contribute to leukemogenesis and explain the aptitude of leukemic lymphoblasts to expand outside the bone marrow microenvironment.

[1]  F. Behm,et al.  Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. , 1992, Blood.

[2]  S. Jhanwar,et al.  Distinct patterns of chromosome abnormalities characterize childhood non‐Hodgkin's lymphoma , 1992, British journal of haematology.

[3]  V. Fadok,et al.  Apoptosis and programmed cell death in immunity. , 1992, Annual review of immunology.

[4]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[5]  T. Lebien,et al.  Development of a bone marrow culture for maintenance and growth of normal human B cell precursors. , 1991, Journal of immunology.

[6]  J. Banchereau,et al.  Interleukin-7 induces the proliferation of normal human B-cell precursors , 1991 .

[7]  A. Rolink,et al.  Molecular and cellular origins of B lymphocyte diversity , 1991, Cell.

[8]  C. Abboud,et al.  Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. , 1991, The Journal of clinical investigation.

[9]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Maclennan,et al.  Germinal center cells express bcl‐2 protein after activation by signals which prevent their entry into apoptosis , 1991, European journal of immunology.

[11]  Gwyn T. Williams Programmed cell death: Apoptosis and oncogenesis , 1991, Cell.

[12]  Christopher T Denny,et al.  Leukemia and the disruption of normal hematopoiesis , 1991, Cell.

[13]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[14]  J. Giorgi,et al.  A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. , 1991, Cytometry.

[15]  D. Mason,et al.  Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation , 1990, The Lancet.

[16]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[17]  D. G. Osmond,et al.  Microenvironmental organization and stromal cell associations of B lymphocyte precursor cells in mouse bone marrow , 1990, European journal of immunology.

[18]  A. Boyd,et al.  Cloned stromal cell lines derived from human Whitlock/Witte-type long-term bone marrow cultures. , 1990, Experimental hematology.

[19]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[20]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[21]  M. Koury,et al.  Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.

[22]  T. Dexter,et al.  Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis , 1990, Nature.

[23]  I. Maclennan,et al.  Mechanism of antigen-driven selection in germinal centres , 1989, Nature.

[24]  F. Alt,et al.  Molecular characterization of the lymphoid V(D)J recombination activity. , 1989, The Journal of biological chemistry.

[25]  M. Lavin,et al.  Cell death by apoptosis in acute leukaemia , 1989, The Journal of pathology.

[26]  D. Campana,et al.  The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. , 1989, Leukemia.

[27]  P. Nowell,et al.  Oncogenic potential of bcl-2 demonstrated by gene transfer , 1988, Nature.

[28]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[29]  A. Carroll,et al.  Bone marrow origin of a B-cell lymphoma , 1988 .

[30]  D. Campana,et al.  Proliferation of normal and malignant human immature lymphoid cells , 1988 .

[31]  A. Carroll,et al.  Bone marrow origin of a B-cell lymphoma. , 1988, Blood.

[32]  S. Korsmeyer,et al.  Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Greaves Differentiation-linked leukemogenesis in lymphocytes. , 1986, Science.

[34]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[35]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[37]  M. Oken,et al.  Recurrent chromosomal defects are found in most patients with non-Hodgkin's-lymphoma. , 1984, Cancer genetics and cytogenetics.

[38]  K A Muirhead,et al.  Determination of linear fluorescence intensities from flow cytometric data accumulated with logarithmic amplifiers. , 1983, Cytometry.

[39]  W. Knapp,et al.  Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas. , 1982, Leukemia research.